LS
Lisata Therapeutics, Inc.
LSTA · NASDAQ
$1.56 -4.88% (-$0.08)
1M -11.36%
Market Cap $14.2M
P/E Ratio -
Div. Yield -
ROE 113.79%
Piotroski F-Score Weak
1/9Valuation
47 /100
Fair P/B 1.72x
P/S 142.06x
P/FFO N/A
Growth
0 /100
Declining Book val. growth 39.35%
Rev. growth N/A
FCF growth N/A
Profitability
20 /100
Weak Net margin 14,621.00%
Op. margin 16,427.00%
FCF margin 12,323.00%
Quality
0 /100
Poor ROE 113.79%
ROA 132.59%
Asset turnover 0.01x
Debt
100 /100
Low Current ratio 3.69x
Debt/Equity 0.00x
Net debt/EBITDA N/A
Stability
61 /100
Moderate EPS volatility 36.23%
Profitable years 0
Beta 0.80x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LSTA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David J. Mazzo
Employees
21
Headquarters
Basking Ridge
Upcoming events
05 NOV
Earnings
Upcoming earnings report